Artificial intelligence in predicting recurrence after first-line treatment of liver cancer: a systematic review and meta-analysis.

IF 2.9 3区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING BMC Medical Imaging Pub Date : 2024-10-07 DOI:10.1186/s12880-024-01440-z

Linyong Wu, Qingfeng Lai, Songhua Li, Shaofeng Wu, Yizhong Li, Ju Huang, Qiuli Zeng, Dayou Wei

{"title":"Artificial intelligence in predicting recurrence after first-line treatment of liver cancer: a systematic review and meta-analysis.","authors":"Linyong Wu, Qingfeng Lai, Songhua Li, Shaofeng Wu, Yizhong Li, Ju Huang, Qiuli Zeng, Dayou Wei","doi":"10.1186/s12880-024-01440-z","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to conduct a systematic review and meta-analysis to comprehensively evaluate the performance and methodological quality of artificial intelligence (AI) in predicting recurrence after single first-line treatment for liver cancer.Methods: A rigorous and systematic evaluation was conducted on the AI studies related to recurrence after single first-line treatment for liver cancer, retrieved from the PubMed, Embase, Web of Science, Cochrane Library, and CNKI databases. The area under the curve (AUC), sensitivity (SENC), and specificity (SPEC) of each study were extracted for meta-analysis.Results: Six percutaneous ablation (PA) studies, 16 surgical resection (SR) studies, and 5 transarterial chemoembolization (TACE) studies were included in the meta-analysis for predicting recurrence after hepatocellular carcinoma (HCC) treatment, respectively. Four SR studies and 2 PA studies were included in the meta-analysis for recurrence after intrahepatic cholangiocarcinoma (ICC) and colorectal cancer liver metastasis (CRLM) treatment. The pooled SENC, SEPC, and AUC of AI in predicting recurrence after primary HCC treatment via PA, SR, and TACE were 0.78, 0.90, and 0.92; 0.81, 0.77, and 0.86; and 0.73, 0.79, and 0.79, respectively. The values for ICC treated with SR and CRLM treated with PA were 0.85, 0.71, 0.86 and 0.69, 0.63,0.74, respectively.Conclusion: This systematic review and meta-analysis demonstrates the comprehensive application value of AI in predicting recurrence after a single first-line treatment of liver cancer, with satisfactory results, indicating the clinical translation potential of AI in predicting recurrence after liver cancer treatment.","PeriodicalId":9020,"journal":{"name":"BMC Medical Imaging","volume":"24 1","pages":"263"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457388/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medical Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12880-024-01440-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study was to conduct a systematic review and meta-analysis to comprehensively evaluate the performance and methodological quality of artificial intelligence (AI) in predicting recurrence after single first-line treatment for liver cancer.

Methods: A rigorous and systematic evaluation was conducted on the AI studies related to recurrence after single first-line treatment for liver cancer, retrieved from the PubMed, Embase, Web of Science, Cochrane Library, and CNKI databases. The area under the curve (AUC), sensitivity (SENC), and specificity (SPEC) of each study were extracted for meta-analysis.

Results: Six percutaneous ablation (PA) studies, 16 surgical resection (SR) studies, and 5 transarterial chemoembolization (TACE) studies were included in the meta-analysis for predicting recurrence after hepatocellular carcinoma (HCC) treatment, respectively. Four SR studies and 2 PA studies were included in the meta-analysis for recurrence after intrahepatic cholangiocarcinoma (ICC) and colorectal cancer liver metastasis (CRLM) treatment. The pooled SENC, SEPC, and AUC of AI in predicting recurrence after primary HCC treatment via PA, SR, and TACE were 0.78, 0.90, and 0.92; 0.81, 0.77, and 0.86; and 0.73, 0.79, and 0.79, respectively. The values for ICC treated with SR and CRLM treated with PA were 0.85, 0.71, 0.86 and 0.69, 0.63,0.74, respectively.

Conclusion: This systematic review and meta-analysis demonstrates the comprehensive application value of AI in predicting recurrence after a single first-line treatment of liver cancer, with satisfactory results, indicating the clinical translation potential of AI in predicting recurrence after liver cancer treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

人工智能预测肝癌一线治疗后的复发：系统综述和荟萃分析。

研究背景本研究旨在进行系统综述和荟萃分析，以全面评估人工智能（AI）在预测肝癌单次一线治疗后复发方面的性能和方法学质量：对从PubMed、Embase、Web of Science、Cochrane Library和CNKI数据库中检索到的与肝癌单次一线治疗后复发相关的人工智能研究进行了严格而系统的评估。提取每项研究的曲线下面积（AUC）、敏感性（SENC）和特异性（SPEC）进行荟萃分析：结果：6 项经皮消融术（PA）研究、16 项手术切除术（SR）研究和 5 项经动脉化疗栓塞术（TACE）研究分别被纳入了预测肝细胞癌（HCC）治疗后复发的荟萃分析。针对肝内胆管癌（ICC）和结直肠癌肝转移（CRLM）治疗后复发的荟萃分析纳入了 4 项 SR 研究和 2 项 PA 研究。AI预测PA、SR和TACE治疗原发性HCC后复发的汇总SENC、SEPC和AUC分别为0.78、0.90和0.92；0.81、0.77和0.86；0.73、0.79和0.79。SR治疗的ICC和PA治疗的CRLM的数值分别为0.85、0.71、0.86和0.69、0.63、0.74：本系统综述和荟萃分析展示了人工智能在预测肝癌单次一线治疗后复发的综合应用价值，结果令人满意，表明人工智能在预测肝癌治疗后复发方面具有临床转化潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Medical Imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

4.60

自引率

3.70%

发文量

198

审稿时长

27 weeks

期刊介绍： BMC Medical Imaging is an open access journal publishing original peer-reviewed research articles in the development, evaluation, and use of imaging techniques and image processing tools to diagnose and manage disease.